Latest Intelligence on Oncology in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor
09 Apr 2001
CommentWire
CommentWire

Abbott: positive results for prostate cancer drug

Published By Datamonitor
04 Jun 2001
CommentWire
CommentWire

Abbott: Xinlay unlikely to challenge Taxotere's dominance

Abbott's Xinlay has been granted fast track status by the FDA for the treatment of metastatic hormone-refractory prostate cancer. The treatment's favorable toxicity profile and oral formulation mean that, if approved, uptake should be strong. However, Aventis's Taxotere could become the gold standard and Abbott will need to provide solid survival data if Xinlay is to rival Taxotere's success.

Published By Datamonitor
12 Jul 2004
CommentWire
CommentWire

Abgenix/Amgen: colon cancer drug could challenge Erbitux

Abgenix and Amgen plan to submit an application to market colon cancer drug panitumumab by the end of 2005 after US regulators awarded the drug fast track status. With this indication already dominated by Genentech's Avastin and ImClone's Erbitux, panitumumab will need to demonstrate a survival advantage in phase III testing in order to establish itself in the colon cancer drug market.

Published By Datamonitor
03 Aug 2005
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002
CommentWire
CommentWire

Abraxis: clear regulatory pathway for Abraxane in lung cancer

Abraxis has reached an agreement with the FDA under the special protocol assessment process for a pivotal trial involving Abraxane. The Phase III non-small cell lung cancer trial will investigate this albumin-bound paclitaxel reformulation in the first-line setting. The agreement provides a clear pathway for horizontal expansion for Abraxane if the trial endpoints are achieved.

Published By Datamonitor
17 Oct 2007
Expert View
Expert View

Adult acute leukemia: demand for innovative drugs that prolong survival

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.

Published By Datamonitor
11 May 2006
CommentWire
CommentWire

AEterna: new niche for Neovastat

Published By Datamonitor
22 Dec 2000
CommentWire
CommentWire

Allos Therapeutics: targeting underserved cancer market

Following positive results from the pivotal Phase II PROPEL trial, pralatrexate has been filed for FDA approval in second-line and higher peripheral T-cell lymphoma treatment. If pralatrexate is approved, its resulting first-to-market status may facilitate its uptake in this underserved patient population and pave the way for extension into more lucrative indications.

Published By Datamonitor
26 Mar 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.